 Lisa Kosmiski
Concepts (171)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Energy Metabolism | 7 | 2013 | 730 | 1.360 |
Why?
| | HIV-Associated Lipodystrophy Syndrome | 6 | 2012 | 17 | 1.190 |
Why?
| | HIV Infections | 12 | 2012 | 2470 | 1.160 |
Why?
| | Rest | 3 | 2013 | 105 | 0.880 |
Why?
| | Lipodystrophy | 3 | 2011 | 16 | 0.870 |
Why?
| | Thiazolidinediones | 5 | 2016 | 143 | 0.690 |
Why?
| | Basal Metabolism | 2 | 2011 | 46 | 0.670 |
Why?
| | Subcutaneous Fat | 2 | 2011 | 71 | 0.660 |
Why?
| | Energy Intake | 2 | 2011 | 420 | 0.570 |
Why?
| | HIV Protease Inhibitors | 4 | 2011 | 64 | 0.560 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 3 | 2013 | 41 | 0.520 |
Why?
| | Adiponectin | 4 | 2016 | 212 | 0.510 |
Why?
| | Leptin | 2 | 2007 | 212 | 0.460 |
Why?
| | Starvation | 1 | 2013 | 21 | 0.450 |
Why?
| | Anorexia Nervosa | 1 | 2013 | 69 | 0.420 |
Why?
| | Adipocytes | 2 | 2006 | 189 | 0.420 |
Why?
| | Organic Anion Transporters | 2 | 2011 | 15 | 0.420 |
Why?
| | Adaptation, Physiological | 2 | 2013 | 481 | 0.400 |
Why?
| | Body Fat Distribution | 1 | 2011 | 44 | 0.390 |
Why?
| | Nutritional Requirements | 1 | 2011 | 72 | 0.380 |
Why?
| | Polymorphism, Genetic | 4 | 2013 | 618 | 0.380 |
Why?
| | Adipose Tissue, Brown | 1 | 2011 | 68 | 0.370 |
Why?
| | Reverse Transcriptase Inhibitors | 2 | 2012 | 82 | 0.360 |
Why?
| | HIV | 2 | 2011 | 208 | 0.350 |
Why?
| | Adipose Tissue | 4 | 2012 | 558 | 0.340 |
Why?
| | Absorptiometry, Photon | 1 | 2009 | 223 | 0.320 |
Why?
| | Body Composition | 6 | 2013 | 586 | 0.320 |
Why?
| | Health | 1 | 2008 | 74 | 0.300 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2011 | 288 | 0.300 |
Why?
| | Calorimetry, Indirect | 4 | 2011 | 70 | 0.290 |
Why?
| | Body Temperature Regulation | 1 | 2007 | 72 | 0.280 |
Why?
| | Antiretroviral Therapy, Highly Active | 2 | 2006 | 256 | 0.280 |
Why?
| | Adult | 21 | 2016 | 30711 | 0.260 |
Why?
| | Caloric Restriction | 1 | 2007 | 90 | 0.260 |
Why?
| | Anti-HIV Agents | 3 | 2012 | 668 | 0.260 |
Why?
| | Body Mass Index | 6 | 2013 | 1968 | 0.240 |
Why?
| | Blood Glucose | 3 | 2016 | 1823 | 0.240 |
Why?
| | Hypoglycemic Agents | 4 | 2016 | 1006 | 0.230 |
Why?
| | Metabolic Syndrome | 3 | 2016 | 324 | 0.230 |
Why?
| | Glucose Tolerance Test | 4 | 2011 | 344 | 0.230 |
Why?
| | Middle Aged | 17 | 2016 | 26873 | 0.230 |
Why?
| | Lipid Metabolism | 1 | 2006 | 449 | 0.210 |
Why?
| | Pancreatitis | 1 | 2003 | 107 | 0.200 |
Why?
| | Dietary Carbohydrates | 1 | 2003 | 136 | 0.200 |
Why?
| | Male | 22 | 2016 | 55814 | 0.200 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2003 | 349 | 0.190 |
Why?
| | Regression Analysis | 3 | 2011 | 949 | 0.170 |
Why?
| | Female | 19 | 2016 | 59720 | 0.160 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2013 | 372 | 0.150 |
Why?
| | Body Weight | 4 | 2016 | 875 | 0.150 |
Why?
| | Humans | 24 | 2016 | 115222 | 0.140 |
Why?
| | Cross-Sectional Studies | 4 | 2013 | 4419 | 0.140 |
Why?
| | Proteins | 1 | 2003 | 915 | 0.140 |
Why?
| | Cytochrome P-450 CYP2C8 | 3 | 2013 | 15 | 0.130 |
Why?
| | Lectins | 1 | 2016 | 44 | 0.130 |
Why?
| | Drug Therapy, Combination | 3 | 2012 | 959 | 0.130 |
Why?
| | Case-Control Studies | 2 | 2013 | 3023 | 0.130 |
Why?
| | CD4 Lymphocyte Count | 3 | 2010 | 257 | 0.120 |
Why?
| | Ritonavir | 2 | 2012 | 71 | 0.120 |
Why?
| | HIV-1 | 3 | 2012 | 768 | 0.110 |
Why?
| | Gemfibrozil | 1 | 2013 | 10 | 0.110 |
Why?
| | Heptanoic Acids | 1 | 2013 | 60 | 0.110 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2006 | 2098 | 0.100 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2013 | 43 | 0.100 |
Why?
| | Pyrazines | 1 | 2013 | 71 | 0.100 |
Why?
| | Hypolipidemic Agents | 1 | 2013 | 87 | 0.100 |
Why?
| | Area Under Curve | 2 | 2013 | 275 | 0.100 |
Why?
| | Resistin | 2 | 2010 | 12 | 0.100 |
Why?
| | Pravastatin | 1 | 2011 | 28 | 0.100 |
Why?
| | Wasting Syndrome | 1 | 2011 | 11 | 0.100 |
Why?
| | Pyrroles | 1 | 2013 | 183 | 0.100 |
Why?
| | Triazoles | 1 | 2013 | 130 | 0.100 |
Why?
| | Tomography | 1 | 2011 | 21 | 0.100 |
Why?
| | DNA, Mitochondrial | 1 | 2012 | 183 | 0.100 |
Why?
| | Torso | 1 | 2011 | 30 | 0.100 |
Why?
| | Thermogenesis | 1 | 2011 | 40 | 0.090 |
Why?
| | Uridine | 1 | 2010 | 29 | 0.090 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2011 | 117 | 0.090 |
Why?
| | Lactation | 1 | 2011 | 149 | 0.090 |
Why?
| | Coinfection | 1 | 2011 | 120 | 0.090 |
Why?
| | Glucose Intolerance | 1 | 2011 | 137 | 0.090 |
Why?
| | Pilot Projects | 2 | 2011 | 1377 | 0.090 |
Why?
| | Leg | 1 | 2011 | 228 | 0.090 |
Why?
| | Triglycerides | 2 | 2011 | 472 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 2 | 2011 | 3128 | 0.080 |
Why?
| | Chemokine CXCL5 | 1 | 2008 | 12 | 0.080 |
Why?
| | Sulfonamides | 1 | 2011 | 445 | 0.080 |
Why?
| | Cytokines | 1 | 2016 | 1843 | 0.080 |
Why?
| | Chemokine CCL2 | 1 | 2008 | 105 | 0.070 |
Why?
| | Chronic Disease | 1 | 2013 | 1594 | 0.070 |
Why?
| | Genotype | 2 | 2013 | 1781 | 0.070 |
Why?
| | Postprandial Period | 1 | 2007 | 88 | 0.070 |
Why?
| | Drug Interactions | 3 | 2013 | 347 | 0.070 |
Why?
| | Insulin Resistance | 3 | 2010 | 1079 | 0.070 |
Why?
| | Pulmonary Gas Exchange | 1 | 2007 | 117 | 0.070 |
Why?
| | Glyburide | 1 | 2006 | 35 | 0.070 |
Why?
| | 3T3-L1 Cells | 1 | 2006 | 31 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 1902 | 0.060 |
Why?
| | Prevalence | 1 | 2011 | 2257 | 0.060 |
Why?
| | Viral Load | 2 | 2010 | 405 | 0.060 |
Why?
| | Cohort Studies | 2 | 2013 | 4917 | 0.060 |
Why?
| | Eating | 1 | 2007 | 347 | 0.060 |
Why?
| | Analysis of Variance | 1 | 2007 | 1231 | 0.060 |
Why?
| | Double-Blind Method | 3 | 2016 | 1665 | 0.060 |
Why?
| | Adolescent | 3 | 2011 | 17889 | 0.060 |
Why?
| | Diabetes Mellitus | 1 | 2011 | 909 | 0.060 |
Why?
| | Hypertriglyceridemia | 1 | 2003 | 34 | 0.050 |
Why?
| | Waist Circumference | 2 | 2016 | 123 | 0.050 |
Why?
| | Cell Survival | 1 | 2006 | 1022 | 0.050 |
Why?
| | Metformin | 1 | 2006 | 278 | 0.050 |
Why?
| | Time Factors | 2 | 2010 | 6157 | 0.050 |
Why?
| | Young Adult | 2 | 2013 | 10520 | 0.050 |
Why?
| | Cross-Over Studies | 2 | 2013 | 442 | 0.050 |
Why?
| | Acute Disease | 1 | 2003 | 918 | 0.040 |
Why?
| | Pregnancy | 1 | 2011 | 5525 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2003 | 926 | 0.040 |
Why?
| | Kinetics | 1 | 2003 | 1558 | 0.040 |
Why?
| | Lipids | 2 | 2016 | 587 | 0.040 |
Why?
| | Hyperlipoproteinemias | 1 | 1998 | 6 | 0.040 |
Why?
| | Cell Differentiation | 1 | 2006 | 1700 | 0.040 |
Why?
| | RNA, Viral | 1 | 2001 | 567 | 0.040 |
Why?
| | Sleep | 1 | 2003 | 631 | 0.040 |
Why?
| | Blood Pressure | 2 | 2016 | 1540 | 0.040 |
Why?
| | Apoptosis | 1 | 2006 | 2368 | 0.030 |
Why?
| | GPI-Linked Proteins | 1 | 2016 | 56 | 0.030 |
Why?
| | Diet | 1 | 2003 | 1075 | 0.030 |
Why?
| | United States | 1 | 2011 | 12256 | 0.030 |
Why?
| | Administration, Oral | 1 | 2016 | 731 | 0.030 |
Why?
| | Sitagliptin Phosphate | 1 | 2013 | 30 | 0.030 |
Why?
| | Biotransformation | 1 | 2013 | 50 | 0.030 |
Why?
| | Metabolic Clearance Rate | 1 | 2013 | 106 | 0.030 |
Why?
| | Dideoxynucleosides | 1 | 2012 | 20 | 0.030 |
Why?
| | Half-Life | 1 | 2013 | 143 | 0.030 |
Why?
| | Benzoxazines | 1 | 2012 | 28 | 0.030 |
Why?
| | Cyclopropanes | 1 | 2012 | 81 | 0.030 |
Why?
| | Atazanavir Sulfate | 1 | 2012 | 41 | 0.030 |
Why?
| | Lamivudine | 1 | 2012 | 59 | 0.030 |
Why?
| | Alkynes | 1 | 2012 | 53 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2013 | 197 | 0.030 |
Why?
| | Organophosphonates | 1 | 2012 | 90 | 0.030 |
Why?
| | Gene Frequency | 1 | 2013 | 483 | 0.020 |
Why?
| | Deoxycytidine | 1 | 2012 | 138 | 0.020 |
Why?
| | Darunavir | 1 | 2011 | 17 | 0.020 |
Why?
| | Drug Combinations | 1 | 2012 | 287 | 0.020 |
Why?
| | Emtricitabine | 1 | 2012 | 147 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2016 | 1860 | 0.020 |
Why?
| | Tenofovir | 1 | 2012 | 204 | 0.020 |
Why?
| | Oligopeptides | 1 | 2012 | 234 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2013 | 344 | 0.020 |
Why?
| | Adenine | 1 | 2012 | 220 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2016 | 9151 | 0.020 |
Why?
| | Haplotypes | 1 | 2011 | 455 | 0.020 |
Why?
| | Cholesterol | 1 | 2011 | 369 | 0.020 |
Why?
| | Mice | 1 | 2006 | 14934 | 0.020 |
Why?
| | Pyridines | 1 | 2012 | 424 | 0.020 |
Why?
| | Lipoproteins | 1 | 2010 | 160 | 0.020 |
Why?
| | Mitochondria | 1 | 2012 | 750 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2003 | 12597 | 0.020 |
Why?
| | Medication Adherence | 1 | 2010 | 537 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2008 | 363 | 0.020 |
Why?
| | Prospective Studies | 1 | 2016 | 6245 | 0.010 |
Why?
| | Animals | 1 | 2006 | 31884 | 0.010 |
Why?
| | Colorado | 1 | 2013 | 4099 | 0.010 |
Why?
| | Biomarkers | 1 | 2010 | 3422 | 0.010 |
Why?
| | Quality of Life | 1 | 2010 | 2364 | 0.010 |
Why?
| | Retinoids | 1 | 1998 | 31 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2010 | 1731 | 0.010 |
Why?
| | Steroids | 1 | 1998 | 147 | 0.010 |
Why?
| | Parenteral Nutrition | 1 | 1998 | 93 | 0.010 |
Why?
| | Antihypertensive Agents | 1 | 1998 | 430 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 1998 | 667 | 0.010 |
Why?
|
|
Kosmiski's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|